Ring Therapeutics

Ring Therapeutics is a biotechnology company, founded in 2017, with the aim of revolutionizing gene therapy. Their recent achievement includes securing an impressive $86.50M Series C investment on 09 March 2023, with participation from prominent investors such as Flagship Pioneering, Invus, Partners Investment, T. Rowe Price, Alexandria Venture Investments, CJ Investment, Altitude Life Science Ventures, UPMC Enterprises, and Kyowa Kirin. The company, a United States-based operation, is backed by Flagship Pioneering, which validates the potential and credibility of Ring Therapeutics. Their dedication to biotechnology, health care, and health and wellness is evident in their commitment to power a new era of gene therapy. This innovative approach positions them as a noteworthy player in the biotech industry. Additionally, their emphasis on privacy, emphasized in their statement about not soliciting sensitive personal information via email or social media platforms, showcases their dedication to ethics and confidentiality. In conclusion, Ring Therapeutics' recent Series C funding indicates a strong investor confidence in their vision and potential, and with the support of leading investors, they are poised to make significant strides in the gene therapy space.